aflibercept-ayyh (Pavblu) vs Brolucizumab-Dbll

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Age-Related Macular Degeneration

Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline

aflibercept-ayyh (Pavblu)

Marketed by Amgen

Approved in Age-Related Macular Degenerationfusion protein
Reliable signal

NCT04270747 · Phase 3 · completed

This was a randomized, double-masked, active-controlled trial with 576 participants, comparing ABP 938 with aflibercept. The clinical primary endpoint was met for similarity: the 90% confidence interval for the treatment difference in Week 8 visual-acuity change (-1.1 to 1.3 ETDRS letters) was entirely within the prespecified -3 to 3 letter margin.

Reported efficacy

Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): ABP 938 6.4 Letters (Standard Deviation 8.18) vs Aflibercept 6.5 Letters (Standard Deviation 8.97) (met)

Result source: NCT04270747

Brolucizumab-Dbll

Marketed by Novartis and partners

Approved in Age-Related Macular Degenerationantibody fragment (scFv)
Weak signal

NCT05672979 · Phase 3 · status unknown

This is a single-arm, unblinded study with no placebo or active comparator, so it cannot establish how much of any visual acuity change is attributable to brolucizumab itself. Results are not yet available.

No aligned efficacy figure on record for this race.

Results for Age-Related Macular Degeneration

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Brolucizumab-Dbll: registry results are on file for Age-Related Macular Degeneration, but their comparison mappings are not yet available.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

aflibercept-ayyh (Pavblu)

BCVA Change Letters 6.4 vs 6.5 Aflibercept Letters @ 8wk
absolute change · Letters
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 8 more results
5 vs 5.4 Aflibercept Letters @ 4wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
6.5 vs 7.6 Aflibercept Letters @ 8wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
6.8 vs 7.5 Aflibercept Letters @ 16wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.2 vs 7.1 Aflibercept Letters @ 24wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.1 vs 8.7 Aflibercept Letters @ 32wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.3 vs 8.1 Aflibercept Letters @ 40wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.2 vs 8.7 Aflibercept Letters @ 48wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.6 vs 9.4 Aflibercept Letters @ 52wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Maintained Vision 95.6% (n=251) vs 97.6% (n=125) Aflibercept @ 52wk
responder rate · % of participants
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Gain 10 Letters 29.4% (n=279) vs 32.7% (n=281) Aflibercept @ 8wk
responder rate · % of participants
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Gain 15 Letters 24.3% (n=251) vs 29.6% (n=125) Aflibercept @ 52wk
responder rate · % of participants
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
CNV Area Change Mm2 -4.962 vs -5.479 Aflibercept mm @ 8wk
absolute change · mm
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 3 more results
-4.089 vs -5.174 Aflibercept mm @ 16wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-4.323 vs -5.308 Aflibercept mm @ 24wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-6.276 vs -7.28 Aflibercept mm @ 52wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
CST Change Microns -136.5 vs -143.1 Aflibercept m @ 4wk
absolute change · m
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 7 more results
-145.9 vs -146.3 Aflibercept m @ 8wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-125.2 vs -127.3 Aflibercept m @ 16wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-130.8 vs -131.7 Aflibercept m @ 24wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-133.2 vs -134.1 Aflibercept m @ 32wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-132.3 vs -135.6 Aflibercept m @ 40wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-132.3 vs -141.1 Aflibercept m @ 48wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-157.1 vs -159.1 Aflibercept m @ 52wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
Available safety results

aflibercept-ayyh (Pavblu)

Dropout rate
5.2%ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
—Post Week 16: ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
—Through Week 16: ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
Discontinued due to AEs
0.3%ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
—Post Week 16: ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
—Through Week 16: ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
Serious AEs
—ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
8.1%Post Week 16: ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2.1%Through Week 16: ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
Most frequent reported AEs
neovascular age-related macular degeneration 5.9%
conjunctival haemorrhage 1.5%
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 1 more result
conjunctival haemorrhage 4.2%
neovascular age-related macular degeneration 2.1%
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3

Wet Age-Related Macular Degeneration

Shared mechanism: VEGF-A · full Wet Age-Related Macular Degeneration pipeline

aflibercept-ayyh (Pavblu)

Marketed by Amgen

Approved in Wet Age-Related Macular Degenerationfusion protein
Reliable signal

NCT04270747 · Phase 3 · completed

This was a randomized, double-masked, active-controlled trial with 576 participants, comparing ABP 938 with aflibercept. The clinical primary endpoint was met for similarity: the 90% confidence interval for the treatment difference in Week 8 visual-acuity change (-1.1 to 1.3 ETDRS letters) was entirely within the prespecified -3 to 3 letter margin.

Reported efficacy

Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): ABP 938 6.4 Letters (Standard Deviation 8.18) vs Aflibercept 6.5 Letters (Standard Deviation 8.97) (met)

Result source: NCT04270747

Brolucizumab-Dbll

Marketed by Novartis and partners

Approved in Wet Age-Related Macular Degenerationantibody fragment (scFv)
Reliable signal

NCT02307682 · Phase 3 · completed

Randomized, double-blind, active-controlled Phase 3 trial in 1,078 treated patients with neovascular AMD; the primary endpoint was change in best-corrected visual acuity at 48 weeks. Both brolucizumab doses met the prespecified non-inferiority margin versus aflibercept (3 mg difference -0.6 letters, 95% CI -2.5 to 1.3; 6 mg difference -0.2 letters, 95% CI -2.1 to 1.8; margin 4 letters), providing strong comparative evidence that brolucizumab is not worse than aflibercept on this functional endpoint.

No aligned efficacy figure on record for this race.

Results for Wet Age-Related Macular Degeneration

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Brolucizumab-Dbll: registry results are on file for Wet Age-Related Macular Degeneration, but their comparison mappings are not yet available.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

aflibercept-ayyh (Pavblu)

BCVA Change Letters 6.4 vs 6.5 Aflibercept Letters @ 8wk
absolute change · Letters
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 8 more results
5 vs 5.4 Aflibercept Letters @ 4wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
6.5 vs 7.6 Aflibercept Letters @ 8wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
6.8 vs 7.5 Aflibercept Letters @ 16wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.2 vs 7.1 Aflibercept Letters @ 24wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.1 vs 8.7 Aflibercept Letters @ 32wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.3 vs 8.1 Aflibercept Letters @ 40wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.2 vs 8.7 Aflibercept Letters @ 48wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.6 vs 9.4 Aflibercept Letters @ 52wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Maintained Vision 95.6% (n=251) vs 97.6% (n=125) Aflibercept @ 52wk
responder rate · % of participants
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Gain 10 Letters 29.4% (n=279) vs 32.7% (n=281) Aflibercept @ 8wk
responder rate · % of participants
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Gain 15 Letters 24.3% (n=251) vs 29.6% (n=125) Aflibercept @ 52wk
responder rate · % of participants
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
CNV Area Change Mm2 -4.962 vs -5.479 Aflibercept mm @ 8wk
absolute change · mm
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 3 more results
-4.089 vs -5.174 Aflibercept mm @ 16wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-4.323 vs -5.308 Aflibercept mm @ 24wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-6.276 vs -7.28 Aflibercept mm @ 52wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
CST Change Microns -136.5 vs -143.1 Aflibercept m @ 4wk
absolute change · m
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 7 more results
-145.9 vs -146.3 Aflibercept m @ 8wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-125.2 vs -127.3 Aflibercept m @ 16wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-130.8 vs -131.7 Aflibercept m @ 24wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-133.2 vs -134.1 Aflibercept m @ 32wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-132.3 vs -135.6 Aflibercept m @ 40wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-132.3 vs -141.1 Aflibercept m @ 48wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-157.1 vs -159.1 Aflibercept m @ 52wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
Available safety results

aflibercept-ayyh (Pavblu)

Dropout rate
5.2%ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
—Post Week 16: ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
—Through Week 16: ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
Discontinued due to AEs
0.3%ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
—Post Week 16: ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
—Through Week 16: ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
Serious AEs
—ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
8.1%Post Week 16: ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2.1%Through Week 16: ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
Most frequent reported AEs
neovascular age-related macular degeneration 5.9%
conjunctival haemorrhage 1.5%
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 1 more result
conjunctival haemorrhage 4.2%
neovascular age-related macular degeneration 2.1%
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3

Diabetic Macular Edema

Shared mechanism: VEGF-A · full Diabetic Macular Edema pipeline

aflibercept-ayyh (Pavblu)

Marketed by Amgen

Approved in Diabetic Macular Edemafusion protein
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Brolucizumab-Dbll

Marketed by Novartis and partners

Approved in Diabetic Macular Edemaantibody fragment (scFv)
Partial signal

NCT04955171 · Phase 3 · status unknown

Randomized, active-comparator trial testing brolucizumab head-to-head against an established anti-VEGF therapy for diabetic macular edema, though masking was limited to participants only and the trial is relatively small. Results are not yet available.

No aligned efficacy figure on record for this race.

Results for Diabetic Macular Edema

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

aflibercept-ayyh (Pavblu): no structured comparison results are available for Diabetic Macular Edema.

Brolucizumab-Dbll: no structured comparison results are available for Diabetic Macular Edema.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: aflibercept-ayyh (Pavblu)'s landscape · Brolucizumab-Dbll's landscape